FOLFIRI

Phase 3Small molecule

Amgen

FOLFIRI is one of 219 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

102

Total Trials

Active Trials

218

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerRecruiting

MalignanciesRecruiting

Colorectal NeoplasmsRecruiting

Neuroendocrine NeoplasmActive, not recruiting

Solid TumorRecruiting

Colorectal Cancer MetastaticNot yet recruiting

Efficacy and SafetyActive, not recruiting

Induction TherapyActive, not recruiting

Chimeric Antigen Receptor T-CellRecruiting

Metastatic Colorectal CancerPhase 3

Recruiting

MalignanciesPreclinical

Recruiting

Colorectal NeoplasmsPhase 1

Recruiting

Neuroendocrine NeoplasmPhase 2

Active, not recruiting

Solid TumorPhase 1

Recruiting

Colorectal Cancer MetastaticPhase 3

Not yet recruiting

Efficacy and SafetyPhase 2

Active, not recruiting

Induction TherapyPhase 2

Active, not recruiting

Chimeric Antigen Receptor T-CellPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

FOLFIRI

Amgen

Phase 3

2 2

Fludara

Sanofi

Preclinical

1 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 5

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 6

Navmi

SSummit Therapeutics

Preclinical

1 7

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Soc

Pfizer

Preclinical

1 9

Tulmimetostat

Novartis

Preclinical

1 10

Carboplatin AUC-5

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Metastatic Colorectal Cancer

NCT06106308

Phase 1Recruiting

Solid Tumor

NCT06179160

Q2 2027

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT07011576

Phase 1Active, not recruiting

Study completion

NCT04485013

Q1 2028

Phase 2Active, not recruiting

Neuroendocrine Neoplasm

NCT05879055

Q2 2028

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT05786924

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer38 trials

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT06867822·27 enrolled

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Terminated·SSymphogen A/S·Phase 1/2·NCT02568046·10 enrolled

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Terminated· Eisai logo

Eisai·Phase 1/2·NCT01133990·5 enrolled

Show 35 more trials

Erbitux MEtastatic Colorectal Cancer Strategy Study

Completed·AArmando Orlandi·Phase 3·NCT02484833·607 enrolled

A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT01937715·18 enrolled

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Unknown status·FFudan University·Phase 2·NCT05634590·68 enrolled

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy

Completed· Amgen logo

Amgen·Phase 2·NCT00332163·95 enrolled

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Completed· Sanofi logo

Sanofi·Phase 3·NCT01571284·781 enrolled

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Completed· Sanofi logo

Sanofi·Phase 3·NCT00561470·1,226 enrolled

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

Recruiting·UUniversity of Campania Luigi Vanvitelli·Phase 3·NCT07389265·480 enrolled

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

Completed· Pfizer logo

Pfizer·Phase 2·NCT00615056·171 enrolled

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00154102·1,221 enrolled

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Not yet recruiting· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 1/2·NCT07391566·99 enrolled

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Recruiting·SSCRI Development Innovations, LLC·Phase 2·NCT07011576·60 enrolled

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

Withdrawn·IInova Health Care Services·Phase 2·NCT06501989

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07318389·100 enrolled

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Completed·CCardiff Oncology·Phase 1/2·NCT03829410·68 enrolled

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT01326000·169 enrolled

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Completed·PPierre Fabre Medicament·Phase 2·NCT05004350·107 enrolled

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

No longer available·CCardiff Oncology··NCT04446793

Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer

Completed·CCentral European Cooperative Oncology Group·Phase 2·NCT00286130·150 enrolled

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Terminated· EMD Serono logo

EMD Serono·Phase 1/2·NCT01085331·16 enrolled

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Terminated·OOncoMed Pharmaceuticals, Inc.·Phase 1·NCT03035253·16 enrolled

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Completed·CCardiff Oncology·Phase 2·NCT05593328·23 enrolled

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07021950·130 enrolled

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00778830·289 enrolled

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01298570·181 enrolled

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT00636610·199 enrolled

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Completed· Amgen logo

Amgen·Phase 1·NCT00101894·119 enrolled

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Terminated·AAB Science·Phase 3·NCT02605044·123 enrolled

FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer

Completed·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT01219920·244 enrolled

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT02305758·130 enrolled

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Active, not recruiting·CCardiff Oncology·Phase 2·NCT06106308·113 enrolled

Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00508404·154 enrolled

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting·DDominik Paul Modest·Phase 3·NCT05008809·507 enrolled

An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer

Recruiting·OOncolytics Biotech·Phase 2·NCT07446322·60 enrolled

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07221357·990 enrolled

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Recruiting· Roche logo

Roche·Phase 1·NCT04929223·542 enrolled

Colorectal Cancer14 trials

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Completed·IInspirna, Inc.·Phase 1·NCT03597581·89 enrolled

Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment

Completed· Amgen logo

Amgen·Phase 2·NCT00411450·116 enrolled

Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00668863·71 enrolled

Show 11 more trials

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT01276379·221 enrolled

Phase 2 Study of DKN-01 in Colorectal Cancer

Completed·LLeap Therapeutics, Inc.·Phase 2·NCT05480306·188 enrolled

A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

Withdrawn· Roche logo

Roche·Phase 2·NCT07323576

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00551213·67 enrolled

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Completed· Sanofi logo

Sanofi·Phase 2·NCT00454116·106 enrolled

Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer

Terminated· EMD Serono logo

EMD Serono·Phase 1·NCT00719199·21 enrolled

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT01704703·72 enrolled

Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.

Completed·RRegione Lombardia·Phase 2·NCT01068132·54 enrolled

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Unknown status·SShanghai Celfuture Biotech Co., Ltd.·Phase 2·NCT05684211·84 enrolled

Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

Unknown status·FFudan University·Phase 2·NCT00839111·43 enrolled

A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00265850·2,334 enrolled

Colorectal Carcinoma4 trials

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02563002·307 enrolled

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Completed· Amgen logo

Amgen·Phase 2·NCT00752570·144 enrolled

4SC-201 (Resminostat) in Advanced Colorectal Carcinoma

Completed·44SC AG·Phase 1/2·NCT01277406·17 enrolled

Show 1 more trial

A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer

Recruiting· Genmab logo

Genmab·Phase 3·NCT07702032·960 enrolled

Chemotherapy3 trials

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT02033551·47 enrolled

Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

Completed· Amgen logo

Amgen·Phase 3·NCT00339183·1,186 enrolled

Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

Terminated·—·Phase 2·NCT03117972·54 enrolled

Maintenance Treatment2 trials

Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

Unknown status·RRuijin Hospital·Phase 2/3·NCT02942706·200 enrolled

Cetuximab Monotherapy Maintenance Treatment in mCRC

Unknown status·RRuijin Hospital·Phase 2/3·NCT02978313·500 enrolled

37 more indications

Gastric Cancer2 trials

Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer

Completed·SSamsung Medical Center·Phase 3·NCT00313872·200 enrolled

Metastatic Gastric Cancer FFCD 03-07

Completed·UUniversity Hospital, Toulouse·Phase 3·NCT00374036·416 enrolled

Treatment2 trials

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Terminated· Novartis logo

Novartis·Phase 2·NCT04952753·204 enrolled

Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT01124630·21 enrolled

Advanced Solid Tumors2 trials

Study of ABT-700 in Subjects With Advanced Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01472016·74 enrolled

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Completed·TTesaro, Inc.·Phase 1·NCT03250832·111 enrolled

Solid Tumor2 trials

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting· Incyte logo

Incyte·Phase 1·NCT05836324·570 enrolled

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting· Incyte logo

Incyte·Phase 1·NCT06179160·710 enrolled

Efficacy and Safety1 trial

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Active, not recruiting·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT05312398·219 enrolled

Intestinal Cancer1 trial

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05087992·13 enrolled

Atorvastatin1 trial

Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI

Withdrawn·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01605344

PDAC1 trial

Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04348045·307 enrolled

Trial1 trial

Phase I Trial of Combination of FOLFIRI and SOM 230

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01434069·16 enrolled

Chimeric Antigen Receptor T-cell1 trial

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Recruiting·CCelyad Oncology SA·Phase 1·NCT03692429·49 enrolled

Hematologic Malignancies1 trial

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Completed· AbbVie logo

AbbVie·Phase 1·NCT03082209·153 enrolled

Induction Therapy1 trial

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT03806309·106 enrolled

Newly Diagnosed1 trial

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated·IIGM Biosciences, Inc.·Phase 1·NCT04553692·272 enrolled

Pancreatic Carcinoma1 trial

Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma

Withdrawn·RRoger Williams Medical Center·Phase 1·NCT04270929

Pancreatic Cancer1 trial

Second Line Chemotherapy for Advanced Pancreatic Cancer

Completed·GGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente·Phase 2·NCT01543412·50 enrolled

Liver Metastases1 trial

Intensified Chemotherapy in CRC After Resection of Liver Metastases

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2/3·NCT00208260·124 enrolled

Second-line Therapy1 trial

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Terminated· Eisai logo

Eisai·Phase 1/2·NCT01347645·82 enrolled

Cancer1 trial

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Completed· Roche logo

Roche·Phase 2·NCT00959647·19 enrolled

Pancreatic Adenocarcinoma1 trial

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Recruiting·—·Phase 2·NCT06747845·68 enrolled

Solid Tumors1 trial

A Study of ABT-165 in Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01946074·101 enrolled

Stage II Colon Cancer1 trial

Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial

Unknown status·IIFOM ETS - The AIRC Institute of Molecular Oncology·Phase 2·NCT04259944·140 enrolled

Neuroendocrine Carcinoma1 trial

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

Completed·HHospices Civils de Lyon·Phase 2·NCT02820857·153 enrolled

Pancreatic1 trial

Switch Maintenance in Pancreatic

Suspended·—·Phase 1/2·NCT05419479·46 enrolled

Adjuvant Chemotherapy1 trial

mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05362617·328 enrolled

Hepatic Impairment1 trial

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Completed·KKaryopharm Therapeutics Inc·Phase 1/2·NCT04256707·126 enrolled

Phase 11 trial

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Completed·OOncoMed Pharmaceuticals, Inc.·Phase 1·NCT02482441·50 enrolled

Immunogenicity1 trial

A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

Completed·GGreen Cross Corporation·Phase 1/2·NCT03454620·53 enrolled

Esophageal Carcinoma1 trial

FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

Completed·YYuhong Li·Phase 2·NCT02023593·35 enrolled

Renal Cancer1 trial

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Completed· Novartis logo

Novartis·Phase 1·NCT03798626·167 enrolled

Pancreas Cancer1 trial

Molecularly Tailored Therapy for Pancreas Cancer

Completed·GGeorgetown University·Phase 2·NCT01888978·19 enrolled

Advanced Neuroendocrine Carcinomas of The Digestive System1 trial

Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin

Terminated·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT07061080·1 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Preclinical·NCT05786924·554 enrolled

Colorectal Neoplasms1 trial

A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06663319·260 enrolled

Colorectal Cancer Metastatic1 trial

FOLFIRI Plus Bevacizuamb With or Without Iparomlimab and Tuvonralimab as Second-Line Treatment for Metastatic Colorectal Cancer: A Randomized Controlled Trial

Not yet recruiting·SSun Yat-sen University·Phase 3·NCT07729605·270 enrolled

Neuroendocrine Neoplasm1 trial

A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm

Active, not recruiting·BBiotheus Inc.·Phase 2·NCT05879055·31 enrolled

Advanced Gastric or EGJ Cancer1 trial

Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - The Phase II/III RAMIRIS Study

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Preclinical·NCT03081143·429 enrolled

Unspecified1 trial

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab, Cetuximab or FOLFIRI Plus Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies

Active, not recruiting·TTizona Therapeutics, Inc·Phase 1·NCT04485013·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 102 trial records for FOLFIRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFIRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFIRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Amgen

FOLFIRI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Metastatic Colorectal Cancer38 trials

Colorectal Cancer14 trials

Colorectal Carcinoma4 trials

Chemotherapy3 trials

Maintenance Treatment2 trials

Gastric Cancer2 trials

Treatment2 trials

Advanced Solid Tumors2 trials

Solid Tumor2 trials

Efficacy and Safety1 trial

Intestinal Cancer1 trial

Atorvastatin1 trial

PDAC1 trial

Trial1 trial

Chimeric Antigen Receptor T-cell1 trial

Hematologic Malignancies1 trial

Induction Therapy1 trial

Newly Diagnosed1 trial

Pancreatic Carcinoma1 trial

Pancreatic Cancer1 trial

Liver Metastases1 trial

Second-line Therapy1 trial

Cancer1 trial

Pancreatic Adenocarcinoma1 trial

Solid Tumors1 trial

Stage II Colon Cancer1 trial

Neuroendocrine Carcinoma1 trial

Pancreatic1 trial

Adjuvant Chemotherapy1 trial

Hepatic Impairment1 trial

Phase 11 trial

Immunogenicity1 trial

Esophageal Carcinoma1 trial

Renal Cancer1 trial

Pancreas Cancer1 trial

Advanced Neuroendocrine Carcinomas of The Digestive System1 trial

Non-Small Cell Lung Cancer1 trial

Colorectal Neoplasms1 trial

Colorectal Cancer Metastatic1 trial

Neuroendocrine Neoplasm1 trial

Advanced Gastric or EGJ Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News